以樹突細胞為主的免疫療法治療在小鼠的殘餘血癌疾病模式(1/2)
Date Issued
2005
Date
2005
Author(s)
周獻堂
DOI
932314B002133
Abstract
Our preliminary results have demonstrated that vaccination with tumor antigen(TA)-pulsed
DCs could induce a specific protective anti-leukemia effect and significantly prolonged
survival of BALB/c mice that were challenged with murine RL male 1 leukemia. Based on
our preliminary data, we propose this study to test that the capacity of DC-based
immunization may have clinical implications as the adjuvant treatment of residual leukemia
after the traditional induction chemotherapy to prevent the recurrence of the disease.
In this year, we have established the murine leukemia model (Figure 1) and by initial
chemotherapy for the established frank leukemia status to induce remission (Figure 2),
monitor relapse or not(Figure 3) and investigate the effect of BM-derived DCs in inducing
tumor-specific immune response. We will evaluate the efficiency of various pulsed (TA or
TA/adeno-IL12) or unpulsed-DCs by both in vitro immune response assays and in vivo antiresidual
leukemia effect. We will also elucidate the novel optimal immunization schedule for
inducing the competent anti-residual tumor immune response.
SDGs
Publisher
臺北市：國立臺灣大學醫學院小兒科
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
932314B002133.pdf
Size
325.95 KB
Format
Adobe PDF
Checksum
(MD5):e4c5649ce5e047e4ae9ddfdf76edfb2e